Kosinska Anna D, Bauer Tanja, Protzer Ulrike
Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany; German Center for Infection research (DZIF), Munich Partner Site, Germany.
Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany; German Center for Infection research (DZIF), Munich Partner Site, Germany.
Curr Opin Virol. 2017 Apr;23:75-81. doi: 10.1016/j.coviro.2017.03.011. Epub 2017 Apr 25.
A therapeutic vaccine is meant to activate the patient's immune system to fight and finally control or ideally eliminate an already established infectious pathogen. Whereas the success of prophylactic vaccination is based on rapid antibody-mediated neutralization of an invading pathogen, control and elimination of persistent viruses such as hepatitis, herpes or papilloma viruses requires multi-specific and polyfunctional effector T cell responses. These are ideally directed against continuously expressed viral antigens to keep the pathogen in check. Activation of a humoral immune response in order to lower viral antigen load and to limit virus spread, however, confers an additional benefit. Therapeutic vaccines are under development for a number of chronic infections and require an intelligent vaccine design. Hepatitis B virus (HBV) infection may serve as a prime example since a spontaneous, immune-mediated recovery of chronic hepatitis B and an elimination of the virus is possible even if it is observed only in very rare cases. In this review, we summarize the current knowledge and potential improvements of therapeutic vaccines for chronic hepatitis B.
治疗性疫苗旨在激活患者的免疫系统,以对抗并最终控制或理想地消除已确立的感染性病原体。预防性疫苗的成功基于抗体介导的对入侵病原体的快速中和,而控制和消除持续性病毒,如肝炎病毒、疱疹病毒或乳头瘤病毒,则需要多特异性和多功能效应T细胞反应。理想情况下,这些反应针对持续表达的病毒抗原,以抑制病原体。然而,激活体液免疫反应以降低病毒抗原负荷并限制病毒传播,具有额外的益处。针对多种慢性感染的治疗性疫苗正在研发中,这需要智能的疫苗设计。乙型肝炎病毒(HBV)感染可以作为一个主要例子,因为即使仅在极少数情况下观察到,慢性乙型肝炎的自发、免疫介导的恢复以及病毒的消除也是可能的。在这篇综述中,我们总结了慢性乙型肝炎治疗性疫苗的当前知识和潜在改进。